Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir. (2023)
Attributed to:
Blood borne viruses
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/jac/dkad247
PubMed Identifier: 37539492
Publication URI: http://europepmc.org/abstract/MED/37539492
Type: Journal Article/Review
Volume: 78
Parent Publication: The Journal of antimicrobial chemotherapy
Issue: 9
ISSN: 0305-7453